Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from managed care entities. The organizations are typically erecting obstacles to reimbursement, such as steep cost restrictions